Celltrion, Inc. (KRX:068270)
South Korea
· Delayed Price · Currency is KRW 178,200
+200 (0.11%)
At close: Sep 29, 2025
Celltrion Revenue
Celltrion had revenue of 961.46B KRW in the quarter ending June 30, 2025, with 9.91% growth. This brings the company's revenue in the last twelve months to 3.75T, up 40.59% year-over-year. In the year 2024, Celltrion had annual revenue of 3.56T with 63.45% growth.
Revenue (ttm)
3,748.95B
Revenue Growth
+40.59%
P/S Ratio
10.46
Revenue / Employee
1.40B
Employees
2,680
Market Cap
39.21T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3,557.30B | 1,380.87B | 63.45% |
| Dec 31, 2023 | 2,176.43B | -107.54B | -4.71% |
| Dec 31, 2022 | 2,283.97B | 390.57B | 20.63% |
| Dec 31, 2021 | 1,893.40B | 44.29B | 2.39% |
| Dec 31, 2020 | 1,849.12B | 720.66B | 63.86% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,031.69B |
| ALTEOGEN | 158.06B |
| Yuhan | 2,165.44B |
| SK Biopharmaceuticals | 620.28B |
| Peptron | 5.18B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| LigaChem Biosciences | 148.28B |
Celltrion News
- 6 days ago - Celltrion (CONI.F) Acquires Imclone Systems to Strengthen U.S. Presence - GuruFocus
- 6 days ago - South Korea's Celltrion unit buys Eli Lilly's production facility for $330M - Seeking Alpha
- 5 months ago - Celltrion to Cancel $72 Million in Shares to Boost Shareholder Value - GuruFocus
- 5 months ago - Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing ... - GuruFocus
- 5 months ago - Shilpa Medicare settles Celltrion arbitration case with $3.4 million agreement - Business Upturn
- 6 months ago - Celltrion’s Remdantry™, previously known as Inflectra®, will be available in Canada as of April 1, 2025 - Financial Post
- 7 months ago - Celltrion’s Infliximab, the First Monoclonal Antibody Biosimilar, Is Now Remdantry™ in Canada - Financial Post
- 10 months ago - FDA approves Celltrion's biosimilar of J&J's Stelara - Seeking Alpha